PMID: 6259059Jan 1, 1981Paper

A possible antihypertensive mechanism of propranolol: antagonism of angiotensin II enhancement of sympathetic nerve transmission through prostaglandins

Hypertension
E K Jackson, W B Campbell

Abstract

The effects of propranolol on angiotensin II (AII) enhancement of sympathetic nerve transmission were investigated in the in situ blood-perfused mesenteric vascular bed of the rat. Angiotensin II in subpressor concentrations (3 ng/ml) potentiated the vasoconstrictor responses to both sympathetic nerve stimulation (NS) and exogenous norepinephrine (NE). The dl-propranolol had no effect on the basal vasoconstrictor responses to NS and NE, yet inhibited the AII-enhanced vasoconstrictor responses to NS by 47% (p less than 0.05) and 81% (p less than 0.001) at 100 and 300 ng/ml respectively. In contrast, the potentiation of NE responses by AII was unaffected by propranolol. A similar blockade of AII enhancement of NS was observed with the d-isomer of propranolol. Dibucaine (300 ng/ml), a local anesthetic, failed to alter the basal or AII-enhanced responses to either NS or NE. Indomethacin, a prostaglandin synthetase inhibitor (5 mg/kg, s.c.), abolished the inhibitory effect of dl-propranolol on AII enhancement of NS. Prostaglandin E2 (PGE2), but not prostaglandin I2, (3 ng/ml) inhibited AII enhancement of NS without altering the basal response to NS or NE in indomethacin-pretreated animals. Intraarterial infusions of dl-propranolol, ...Continue Reading

References

Jul 15, 1976·Biochemical Pharmacology·J T WrightR Taylor
Jun 1, 1978·European Journal of Clinical Investigation·K H RahnW Stephany
Sep 1, 1978·The American Journal of Physiology·J AckerlyM J Peach
Jul 1, 1978·Prostaglandins and Medicine·S Y TanP J Mulrow
Jan 20, 1977·Biochimica Et Biophysica Acta·R K SinhaS Mazumder
Sep 1, 1977·Clinical Pharmacology and Therapeutics·M EslerV DeQuattro
Jul 8, 1976·The New England Journal of Medicine·J W HollifieldD G Shand
Sep 1, 1976·Kidney International·R J AndersonR W Schrier
Jul 29, 1975·European Journal of Clinical Investigation·F DrayJ Maclouf
Apr 1, 1976·Proceedings of the Society for Experimental Biology and Medicine·J AckerlyM J Peach
Jan 1, 1974·Naunyn-Schmiedeberg's Archives of Pharmacology·K H RahnG Planz
May 1, 1967·The Journal of Physiology·C J DICKINSON, R Yu
Dec 1, 1967·Biochemical Pharmacology·D Palaic, P A Khairallah
Jan 1, 1970·Naunyn-Schmiedebergs Archiv Für Pharmakologie·K Starke
Jan 1, 1970·European Journal of Pharmacology·M J PeachP A Khairallah
Feb 1, 1971·British Journal of Pharmacology·J Hughes, R H Roth
Jun 1, 1967·The Journal of Pharmacy and Pharmacology·D Palaic, P A Khairallah
Nov 1, 1970·The Journal of Pharmacy and Pharmacology·A M Barrett, B Nunn
Feb 1, 1972·The Journal of Clinical Endocrinology and Metabolism·A M Michelakis, R G McAllister
Sep 1, 1970·Journal of Pharmaceutical Sciences·G J Kelliher, J P Buckley
Jun 25, 1966·Nature·R Howe, R G Shanks
Sep 19, 1964·British Medical Journal·B N PRICHARD, P M GILLAM

Citations

Jul 1, 1984·Naunyn-Schmiedeberg's Archives of Pharmacology·G J TrachteM J Peach
Nov 27, 1990·European Journal of Pharmacology·P BhandareV Dhume
Oct 1, 1986·Prostaglandins, Leukotrienes, and Medicine·D Van PraagS J Farber
Sep 22, 1988·The New England Journal of Medicine·J A OatesL J Roberts
Jun 1, 1986·Clinical and Experimental Pharmacology & Physiology·S J ArmsworthA J Smith
Jan 1, 1985·Clinical and Experimental Hypertension. Part A, Theory and Practice·M A van BaakJ F Smits
Jan 1, 1987·Clinical and Experimental Hypertension. Part A, Theory and Practice·J F GerkensA J Smith
Dec 31, 1997·The American Journal of the Medical Sciences·A Del RossoA Ieri
Aug 1, 1997·Prostaglandins, Leukotrienes, and Essential Fatty Acids·G K Oriji, H R Keiser
Oct 1, 1984·British Journal of Pharmacology·J F Gerkens, A J Smith
Dec 1, 1983·British Journal of Clinical Pharmacology·G A HurwitzT E Gaffney
Dec 31, 1987·Biochemical and Biophysical Research Communications·M C DattaH A Dowla
Oct 6, 1999·Prostaglandins, Leukotrienes, and Essential Fatty Acids·G K Oriji

Related Concepts

Angiotensin II, Val(5)-
Blood
Hypertensive Disease
Osmosin
Mesenteric Arteries
Structure of Mesenteric Vein
Synaptic Transmission
Norepinephrine, (+, -)-Isomer
Rexigen
Prostaglandin-Endoperoxide Synthase

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.